PMA Supplement Studies Weak, Study Finds, As Past FDA Chief Califf Calls For More Rigor
Executive Summary
The quality of studies used to support panel-track PMA supplement approvals need upgrading, as fewer than half were randomized, blinded or controlled and many relied on surrogate endpoints, says a study published in JAMA. In an accompanying editorial, former FDA commissioner Robert Califf, says it "raises concerns" that the US regulatory system has gotten "too permissive."
You may also be interested in...
White House To Deliver 25 Million Face Masks To Low-Income Americans
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.
HHS Secretary Nominee Becerra Commits To Telehealth Expansion, Procedure Price Transparency
At two recent confirmation hearings, HHS secretary nominee Xavier Becerra promised Senators he would help expand telehealth and procedure price transparency.
US Medicare Agency Makes It Easier For Texas Suppliers To Replace DME Lost To Winter Storms
Durable medical equipment suppliers get temporary HHS and CMS waivers to help Texas Medicare and Medicaid beneficiaries due to the state’s winter storm.